Velcade [bortezomib], thalidomide, dexamethasone (VTD) induction therapy followed by melphalan, prednisone, thalidomide (MPT) maintenance as a first line treatment for the patients with multiple myeloma who are non-transplant candidates
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2016
At a glance
- Drugs Bortezomib; Dexamethasone; Melphalan; Prednisone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 02 Jun 2008 New trial record.